Metabolically Programmed Metal Chelators for Iron Overload
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron chelating agents for treating iron overload diseases have limitations such as poor patient compliance, insufficient iron removal, and side effects like renal toxicity, highlighting the need for more effective and safer metal chelating agents with balanced properties.
Innovation Solution
Development of desazadesferrithiocin analogs that are lipophilic, orally absorbable, and metabolically programmed to convert into hydrophilic, nontoxic metabolites, effectively chelating iron and other metals, thereby addressing the limitations of existing chelating agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If metal chelators are made more lipophilic to improve metal clearing efficiency, then metal clearing efficiency is improved, but toxicity increases
Solution Approach 1:
The patent divides the chelator molecule into two distinct segments: a lipophilic parent chelator structure that enables metal binding and cellular uptake, and a separate hydrophilic metabolite structure that reduces toxicity. This segmentation allows each part to fulfill its specific function - the lipophilic portion improves metal clearing efficiency while the hydrophilic metabolite portion reduces toxicity, thereby resolving the contradiction between these two parameters.
Solution Approach 2:
The patent introduces dynamic transformation of the chelator molecule through metabolic programming. The chelator dynamically changes from a lipophilic form (for effective metal binding and clearance) to a hydrophilic metabolite form (for reduced toxicity). This temporal dynamic allows the same molecule to exhibit different properties at different stages, resolving the contradiction between metal clearing efficiency and toxicity.
2Object-affected harmful factors
If metal chelators are made more hydrophilic to reduce toxicity, then toxicity is reduced, but metal clearing efficiency decreases
Solution Approach 1:
The patent applies preliminary action by pre-programming the chelator molecule with metabolic pathways that will convert it to a hydrophilic form after it has fulfilled its metal-binding function. This allows the chelator to first exert its metal clearing effect (when lipophilic) and then automatically transform to a less toxic hydrophilic metabolite, thereby achieving reduced toxicity without sacrificing metal clearing efficiency.
Solution Approach 2:
The patent introduces dynamic transformation of the chelator molecule through metabolic programming. The chelator dynamically changes from a lipophilic form (for effective metal binding and clearance) to a hydrophilic metabolite form (for reduced toxicity). This temporal dynamic allows the same molecule to exhibit different properties at different stages, resolving the contradiction between metal clearing efficiency and toxicity.
3Reliability
If existing chelating agents are used to treat iron overload, then iron chelation is achieved, but patient compliance is poor due to administration route and frequency
Solution Approach 1:
The patent changes the physicochemical parameters of the chelator molecule, specifically optimizing its lipophilicity to enable oral absorption. This parameter change transforms the administration route from parenteral (injections) to oral, dramatically improving patient compliance while maintaining iron chelation effectiveness through the programmed metabolic conversion to hydrophilic metabolites.
4Reliability
If existing chelating agents are used to treat iron overload, then iron chelation is achieved, but renal toxicity occurs as a side effect
Solution Approach 1:
The patent converts the potential harm of lipophilicity (which could lead to accumulation and renal toxicity) into a benefit by programmatically directing the lipophilic chelator to metabolize into hydrophilic, non-toxic metabolites. This transformation converts what would be a harmful accumulation into a beneficial excretion pathway, eliminating renal toxicity while preserving iron chelation effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The desazadesferrithiocin analogs provide improved metal clearing efficiency and toxicity profile, offering a more effective and safer treatment option for iron overload and other metal-related diseases by balancing lipophilicity, metal clearing efficiency, and toxicity.
Implementation Method 1
The desazadesferrithiocin analogs are able to chelate a metal (e.g., iron and other metals)
Implementation Method 2
they are lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators, which, once absorbed, are converted to hydrophilic, nontoxic metabolites
Data Source
AI summary
The present invention provides compounds of Formula (I), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of Formula (II), which are also “metabolically programmed” metal chelators. The invention also provides pharmaceutical compositions, kits, methods, and uses that include a compound described herein. The compounds, pharmaceutical compositions, kits, and methods may be useful in treating or preventing a disease (e.g., metal overload, oxidative stress, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, reperfusion injury, metal poisoning, or infectious disease).